ImmuCell Corporation Stock Price, News & Analysis (NASDAQ:ICCC)

$8.50 -0.39 (-4.39 %)
(As of 11/17/2017 01:15 AM ET)
Previous Close$8.89
Today's Range$8.47 - $8.83
52-Week Range$5.00 - $9.24
Volume10,149 shs
Average Volume8,011 shs
Market Capitalization$45.41 million
P/E Ratio899
Dividend YieldN/A
Beta1.16

About ImmuCell Corporation (NASDAQ:ICCC)

ImmuCell Corporation logoImmuCell Corporation is an animal health company. The Company operates in the development, acquisition, manufacture and sale of products that improve the health and productivity of cows for the dairy and beef industries segment. The Company has developed products that provide immediate immunity to newborn dairy and beef cattle, and is developing product line extensions of its existing products that address mastitis. The Company's lead product, First Defense, is manufactured from cows' colostrum utilizing its vaccine and milk protein purification technologies. Its Wipe Out Dairy Wipes are made from a non-woven fabric that allows for a vigorous cleaning. It also developed California Mastitis Test (CMT), which is used for bulk tank, as well as individual cow sample monitoring and is used to determine which quarter of the udder is mastitic. Its product development initiative is Mast Out, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows.


Industry, Sector and Symbol:
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Sector: Medical
  • Symbol: NASDAQ:ICCC
  • CUSIP: N/A
  • Web: www.immucell.com
Debt:
  • Debt-to-Equity Ratio: 0.18%
  • Current Ratio: 1.89%
  • Quick Ratio: 1.28%
Price-To-Earnings:
  • Trailing P/E Ratio: 899
Sales & Book Value:
  • Annual Sales: $9.54 million
  • Price / Sales: 4.50
  • Cash Flow: $0.26 per share
  • Price / Cash: 33.31
  • Book Value: $4.07 per share
  • Price / Book: 2.09
Profitability:
  • Trailing EPS: $0.01
  • Net Income: $500,000.00
  • Net Margins: 0.60%
  • Return on Equity: 0.28%
  • Return on Assets: 0.22%
Misc:
  • Employees: 45
  • Outstanding Shares: 5,050,000
 

Frequently Asked Questions for ImmuCell Corporation (NASDAQ:ICCC)

What is ImmuCell Corporation's stock symbol?

ImmuCell Corporation trades on the NASDAQ under the ticker symbol "ICCC."

How were ImmuCell Corporation's earnings last quarter?

ImmuCell Corporation (NASDAQ:ICCC) released its quarterly earnings results on Monday, November, 13th. The biotechnology company reported ($0.07) EPS for the quarter. The biotechnology company had revenue of $2.01 million for the quarter. ImmuCell Corporation had a return on equity of 0.28% and a net margin of 0.60%. View ImmuCell Corporation's Earnings History.

When will ImmuCell Corporation make its next earnings announcement?

ImmuCell Corporation is scheduled to release their next quarterly earnings announcement on Thursday, February, 8th 2018. View Earnings Estimates for ImmuCell Corporation.

Who are some of ImmuCell Corporation's key competitors?

Who are ImmuCell Corporation's key executives?

ImmuCell Corporation's management team includes the folowing people:

  • David Scott Tomsche, Independent Chairman of the Board (Age 59)
  • Michael F. Brigham, President, Chief Executive Officer, Treasurer, Secretary, Director (Age 54)
  • Elizabeth Luttrell Williams, Vice President - Manufacturing Operations
  • Paul R. Wainman, Director (Age 50)
  • David S. Cunningham, Independent Director (Age 49)
  • Jonathan E. Rothschild, Independent Director (Age 61)

Who owns ImmuCell Corporation stock?

ImmuCell Corporation's stock is owned by many different of institutional and retail investors. Top institutional shareholders include ROTHSCHILD JONATHAN E (10.10%) and Essex Investment Management Co. LLC (0.53%). Company insiders that own ImmuCell Corporation stock include Brian L Pessin, David Cunningham, David Scott Tomsche and Joseph H Crabb. View Institutional Ownership Trends for ImmuCell Corporation.

Who bought ImmuCell Corporation stock? Who is buying ImmuCell Corporation stock?

ImmuCell Corporation's stock was acquired by a variety of institutional investors in the last quarter, including Essex Investment Management Co. LLC. Company insiders that have bought ImmuCell Corporation stock in the last two years include Brian L Pessin, David Cunningham and David Scott Tomsche. View Insider Buying and Selling for ImmuCell Corporation.

How do I buy ImmuCell Corporation stock?

Shares of ImmuCell Corporation can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ImmuCell Corporation's stock price today?

One share of ImmuCell Corporation stock can currently be purchased for approximately $8.50.

How big of a company is ImmuCell Corporation?

ImmuCell Corporation has a market capitalization of $45.41 million and generates $9.54 million in revenue each year. The biotechnology company earns $500,000.00 in net income (profit) each year or $0.01 on an earnings per share basis. ImmuCell Corporation employs 45 workers across the globe.

How can I contact ImmuCell Corporation?

ImmuCell Corporation's mailing address is 56 EVERGREEN DR, PORTLAND ME, 04103. The biotechnology company can be reached via phone at 207-878-2770 or via email at [email protected]


MarketBeat Community Rating for ImmuCell Corporation (NASDAQ ICCC)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  32 (Vote Outperform)
Underperform Votes:  25 (Vote Underperform)
Total Votes:  57
MarketBeat's community ratings are surveys of what our community members think about ImmuCell Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for ImmuCell Corporation (NASDAQ:ICCC)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 0 Buy Ratings, 0 Strong Buy RatingsNo ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Analysts' Consensus Price Target: N/A

Consensus Price Target History for ImmuCell Corporation (NASDAQ:ICCC)

Price Target History for ImmuCell Corporation (NASDAQ:ICCC)

Analysts' Ratings History for ImmuCell Corporation (NASDAQ:ICCC)

Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History and Estimates Chart for ImmuCell Corporation (NASDAQ:ICCC)

Earnings by Quarter for ImmuCell Corporation (NASDAQ:ICCC)

Earnings History by Quarter for ImmuCell Corporation (NASDAQ ICCC)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/8/2018        
11/13/2017Q3 2017($0.07)$2.01 millionViewN/AView Earnings Details
8/14/2017Q2 2017($0.05)$1.75 millionViewN/AView Earnings Details
5/11/2017Q1 2017$0.12$3.54 millionViewN/AView Earnings Details
2/9/2017Q416$0.01$2.70 million$2.20 millionViewListenView Earnings Details
11/10/2016Q316$0.01$1.61 million$1.97 millionViewN/AView Earnings Details
5/11/2016Q1$0.11$2.99 millionViewN/AView Earnings Details
2/10/2016Q315$0.09$2.21 million$2.70 millionViewListenView Earnings Details
11/12/2015Q3$0.11$2.47 millionViewListenView Earnings Details
8/13/2015Q215$0.03$1.54 million$1.96 millionViewN/AView Earnings Details
2/11/2015Q414$0.04$1.56 million$2.21 millionViewN/AView Earnings Details
8/12/2014Q214($0.10)$1.37 million$1.54 millionViewN/AView Earnings Details
2/13/2014Q413($0.05)$1.42 million$1.56 millionViewN/AView Earnings Details
11/12/2013Q313$0.02$1.08 million$1.24 millionViewN/AView Earnings Details
11/7/2012Q312($0.02)$1.00 million$1.08 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for ImmuCell Corporation (NASDAQ:ICCC)

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for ImmuCell Corporation (NASDAQ:ICCC)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for ImmuCell Corporation (NASDAQ ICCC)

Insider Ownership Percentage: 20.10%
Institutional Ownership Percentage: 15.88%
Insider Trades by Quarter for ImmuCell Corporation (NASDAQ:ICCC)
Insider Trades by Quarter for ImmuCell Corporation (NASDAQ:ICCC)

Insider Trades by Quarter for ImmuCell Corporation (NASDAQ ICCC)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/27/2017Brian L PessinInsiderBuy30,000$5.25$157,500.00View SEC Filing  
3/14/2017David Scott TomscheDirectorBuy2,000$5.43$10,860.00View SEC Filing  
11/7/2016David Scott TomscheDirectorBuy4,000$5.19$20,760.00View SEC Filing  
7/8/2016Joseph H CrabbVPSell1,935$6.55$12,674.25View SEC Filing  
7/7/2016Joseph H CrabbVPSell2,691$6.58$17,706.78View SEC Filing  
7/5/2016Joseph H CrabbVPSell5,374$6.74$36,220.76View SEC Filing  
3/21/2016David Scott TomscheDirectorBuy955$6.67$6,369.85View SEC Filing  
1/29/2016David CunninghamDirectorBuy1,904$5.25$9,996.00View SEC Filing  
9/3/2015Jonathan E. RothschildDirectorBuy3,000$6.63$19,890.00View SEC Filing  
9/1/2015David Scott TomscheDirectorBuy1,000$6.73$6,730.00View SEC Filing  
8/31/2015Jonathan E. RothschildDirectorBuy6,100$7.37$44,957.00View SEC Filing  
8/28/2015David Scott TomscheDirectorBuy1,500$7.27$10,905.00View SEC Filing  
11/26/2014Jonathan E RothschildDirectorBuy2,100$4.82$10,122.00View SEC Filing  
8/20/2014Jonathan E RothschildDirectorBuy3,000$4.55$13,650.00View SEC Filing  
6/16/2014Jonathan E RothschildDirectorBuy5,901$4.57$26,967.57View SEC Filing  
5/15/2014David CunninghamDirectorBuy1,500$3.91$5,865.00View SEC Filing  
8/23/2013Jonathan E RothschildDirectorBuy1,500$3.98$5,970.00View SEC Filing  
8/16/2013David CunninghamDirectorBuy4,000$3.68$14,720.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for ImmuCell Corporation (NASDAQ:ICCC)

Latest Headlines for ImmuCell Corporation (NASDAQ ICCC)

Source:
DateHeadline
ImmuCell Corporation (ICCC) Releases  Earnings ResultsImmuCell Corporation (ICCC) Releases Earnings Results
www.americanbankingnews.com - November 14 at 9:56 AM
Edited Transcript of ICCC earnings conference call or presentation 13-Nov-17 9:30pm GMTEdited Transcript of ICCC earnings conference call or presentation 13-Nov-17 9:30pm GMT
finance.yahoo.com - November 14 at 5:47 AM
ImmuCell Corps (ICCC) CEO Michael Brigham on Q3 2017 Results - Earnings Call TranscriptImmuCell Corp's (ICCC) CEO Michael Brigham on Q3 2017 Results - Earnings Call Transcript
seekingalpha.com - November 14 at 12:46 AM
Immucell Corp (ICCC) Announces USDA Approval of New Product Claim to Prevent Rotavirus InfectionsImmucell Corp (ICCC) Announces USDA Approval of New Product Claim to Prevent Rotavirus Infections
www.streetinsider.com - November 13 at 7:46 PM
ImmuCell Achieves USDA Approval of New Product Claim to Prevent Rotavirus InfectionsImmuCell Achieves USDA Approval of New Product Claim to Prevent Rotavirus Infections
finance.yahoo.com - November 13 at 7:46 PM
ImmuCell Announces Financial Results for Third Quarter of 2017ImmuCell Announces Financial Results for Third Quarter of 2017
finance.yahoo.com - November 13 at 7:46 PM
ImmuCell Announces Completion of Construction of Nisin Production FacilityImmuCell Announces Completion of Construction of Nisin Production Facility
finance.yahoo.com - November 8 at 10:04 AM
ImmuCell Corporation (ICCC) Scheduled to Post Earnings on MondayImmuCell Corporation (ICCC) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - November 6 at 12:17 PM
ImmuCell to Announce Financial Results for Third Quarter of 2017ImmuCell to Announce Financial Results for Third Quarter of 2017
finance.yahoo.com - November 3 at 8:51 AM
ImmuCell Corp. :ICCC-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017ImmuCell Corp. :ICCC-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017
finance.yahoo.com - October 6 at 8:12 PM
Did ImmuCell Corporation (ICCC) Create Value For Investors Over The Past Year?Did ImmuCell Corporation (ICCC) Create Value For Investors Over The Past Year?
finance.yahoo.com - October 5 at 10:47 AM
ImmuCell Announces Expansion of Sales and Marketing TeamImmuCell Announces Expansion of Sales and Marketing Team
finance.yahoo.com - September 14 at 6:18 AM
ImmuCell Corps (ICCC) CEO Michael Brigham on Q2 2017 Results - Earnings Call TranscriptImmuCell Corp's (ICCC) CEO Michael Brigham on Q2 2017 Results - Earnings Call Transcript
seekingalpha.com - August 15 at 11:55 PM
Edited Transcript of ICCC earnings conference call or presentation 14-Aug-17 8:30pm GMTEdited Transcript of ICCC earnings conference call or presentation 14-Aug-17 8:30pm GMT
finance.yahoo.com - August 15 at 11:55 PM
Investor Network: ImmuCell Corporation to Host Earnings CallInvestor Network: ImmuCell Corporation to Host Earnings Call
finance.yahoo.com - August 14 at 10:03 PM
ImmuCell Announces Financial Results for Second Quarter of 2017ImmuCell Announces Financial Results for Second Quarter of 2017
finance.yahoo.com - August 14 at 10:03 PM
ImmuCell Co. (NASDAQ:ICCC) Announces Quarterly  Earnings ResultsImmuCell Co. (NASDAQ:ICCC) Announces Quarterly Earnings Results
www.americanbankingnews.com - August 14 at 8:22 PM
ImmuCell to Announce Financial Results for Second Quarter of 2017ImmuCell to Announce Financial Results for Second Quarter of 2017
finance.yahoo.com - August 7 at 7:11 PM
Insider Buying: ImmuCell Corporation (ICCC) Insider Buys 30,000 Shares of StockInsider Buying: ImmuCell Corporation (ICCC) Insider Buys 30,000 Shares of Stock
www.americanbankingnews.com - July 28 at 7:35 PM
ImmuCell Closes $1,000,000 Equity InvestmentImmuCell Closes $1,000,000 Equity Investment
finance.yahoo.com - July 27 at 10:14 PM
ImmuCell Unveils New WebsiteImmuCell Unveils New Website
finance.yahoo.com - July 17 at 3:42 PM
ImmuCell Clarifies Number of Authorized Common SharesImmuCell Clarifies Number of Authorized Common Shares
finance.yahoo.com - July 14 at 3:18 AM
IMMUCELL CORP /DE/ Files SEC form 10-K, Annual ReportIMMUCELL CORP /DE/ Files SEC form 10-K, Annual Report
biz.yahoo.com - March 30 at 6:12 PM
IMMUCELL CORP /DE/ Files SEC form 8-K, Change in Directors or Principal Officers, Entry into a Material Definitive AgIMMUCELL CORP /DE/ Files SEC form 8-K, Change in Directors or Principal Officers, Entry into a Material Definitive Ag
biz.yahoo.com - March 8 at 6:36 PM
IMMUCELL CORP /DE/ Files SEC form 8-K, Other EventsIMMUCELL CORP /DE/ Files SEC form 8-K, Other Events
biz.yahoo.com - March 2 at 6:11 PM
ImmuCell Corporation (ICCC)ImmuCell Corporation (ICCC)
seekingalpha.com - February 11 at 5:53 PM
IMMUCELL CORP /DE/ Files SEC form 8-K, Results of Operations and Financial ConditionIMMUCELL CORP /DE/ Files SEC form 8-K, Results of Operations and Financial Condition
biz.yahoo.com - February 10 at 6:34 PM
Q4 2016 ImmuCell Corp Earnings Release - After Market CloseQ4 2016 ImmuCell Corp Earnings Release - After Market Close
biz.yahoo.com - February 9 at 6:43 PM
ImmuCells (ICCC) CEO Michael Brigham on Q3 2016 Results - Earnings Call TranscriptImmuCell's (ICCC) CEO Michael Brigham on Q3 2016 Results - Earnings Call Transcript
seekingalpha.com - November 12 at 8:02 AM
Immucell Corp (ICCC) Reports Q3 EPS of $0.01Immucell Corp (ICCC) Reports Q3 EPS of $0.01
www.streetinsider.com - November 12 at 8:02 AM
IMMUCELL CORP /DE/ Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and ExhibitsIMMUCELL CORP /DE/ Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
biz.yahoo.com - October 21 at 5:39 PM
Immucell Corp (ICCC) Offers Prelim. Q3 Results; Says Sales Fell 20%Immucell Corp (ICCC) Offers Prelim. Q3 Results; Says Sales Fell 20%
www.streetinsider.com - October 19 at 10:27 AM
ImmuCell Announces Preliminary Third Quarter 2016 Financial ResultsImmuCell Announces Preliminary Third Quarter 2016 Financial Results
www.streetinsider.com - October 18 at 10:37 AM
ImmuCell to Raise $3.5 Million in Private PlacementImmuCell to Raise $3.5 Million in Private Placement
www.marketwatch.com - October 18 at 10:37 AM
IMMUCELL CORP /DE/ Files SEC form 8-K, Entry into a Material Definitive AgreementIMMUCELL CORP /DE/ Files SEC form 8-K, Entry into a Material Definitive Agreement
biz.yahoo.com - October 18 at 10:37 AM
ImmuCell Announces Second Quarter 2016 Financial ResultsImmuCell Announces Second Quarter 2016 Financial Results
www.finanznachrichten.de - August 13 at 8:31 AM
ImmuCells (ICCC) CEO Michael Brigham on Q2 2016 Results - Earnings Call TranscriptImmuCell's (ICCC) CEO Michael Brigham on Q2 2016 Results - Earnings Call Transcript
seekingalpha.com - August 13 at 8:31 AM
Immucell Corp (ICCC) Reports Q2 EPS of $0.00Immucell Corp (ICCC) Reports Q2 EPS of $0.00
www.streetinsider.com - August 13 at 8:31 AM
Q2 2016 ImmuCell Corp Earnings Release - After Market CloseQ2 2016 ImmuCell Corp Earnings Release - After Market Close
biz.yahoo.com - August 11 at 8:36 AM
IMMUCELL CORP /DE/ Files SEC form 8-K/A, Submission of Matters to a Vote of Security Holders, Financial Statements anIMMUCELL CORP /DE/ Files SEC form 8-K/A, Submission of Matters to a Vote of Security Holders, Financial Statements an
biz.yahoo.com - June 16 at 3:35 PM

Social Media

Financials

Chart

ImmuCell Corporation (NASDAQ ICCC) Chart for Saturday, November, 18, 2017
Loading chart…

This page was last updated on 11/18/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.